Primary research

3,000 women were followed for 10 years to ask a simple question: does the menopausal transition itself increase the risk of significant anxiety symptoms?

What was done

• Participants were 42–52 years old at the start, pre‑ or early perimenopausal, and then assessed annually for a decade in the SWAN study.
• Anxiety was measured as a cluster of four symptoms (irritability, nervousness/tension, feeling fearful for no reason, heart racing/pounding), rated for frequency over the past two weeks; “high anxiety” was defined as scores in the top 20% (≥4).
• Menopausal stage was classified by bleeding pattern: premenopause, early perimenopause, late perimenopause, postmenopause, and postmenopause while using hormone therapy.
• Analyses adjusted for age, race/ethnicity, education, financial strain, health status, medical conditions, upsetting life events, psychotropic medication use, and vasomotor symptoms (hot flushes/night sweats).

Key results

• In the full sample, odds of high anxiety were higher in every menopausal stage than in premenopause, but once frequent hot flushes/night sweats were included in the model, menopausal stage itself was no longer significant, while frequent vasomotor symptoms nearly tripled the odds of high anxiety.
• When women were split into two groups, patterns diverged:
  • Among women with low anxiety at baseline, risk of high anxiety did increase during early perimenopause, late perimenopause, and postmenopause, even after adjusting for hot flushes and other factors; frequent vasomotor symptoms still roughly doubled the odds.
  • Among women with high anxiety at baseline, menopausal stage did not significantly change anxiety risk; levels of high anxiety remained high across all stages, and here too frequent hot flushes and night sweats were strongly related to high anxiety.

Source: Menopause

• The menopausal transition emerges as a vulnerability window for anxiety in women who were previously low‑anxiety, even when hot flushes, life stress and health factors are taken into account. That fits a view of menopause as a reorganisation of brain–body regulation, not just a hormone “defect.”
• Anxiety in midlife is tightly entwined with vasomotor symptoms, but not reducible to them; for many women, the transition seems to unmask a sensitivity in stress and arousal systems that had been relatively quiet before.
• The data support an approach that treats midlife anxiety as a biological stress‑system shift linked to the transition (especially in previously low‑anxiety women), rather than as “just psychological” or purely oestrogen‑deficiency, aligning with a model that centres nervous‑system load, vasomotor instability, and life context together.